This site is intended for healthcare professionals only

DiabetesontheNet Logo
×

Diabetes &
Primary Care

Issue:

Share this article
Share on facebook
Share on twitter
Share on email
Share on print

The continuing debate on self-monitoring of blood glucose in diabetes

April 2004 saw the publication of a much-needed consensus statement (Owens et al, 2004) on the use of self-monitoring of blood glucose (SMBG) by people with diabetes. Since the publication of the original document, the authors have attempted to obtain a wider consultation by involving healthcare professionals across the UK. This article aims to describe the measures taken to widen the debate in an attempt to provide as clear statements as possible in support of appropriate use of SMBG in people with diabetes.

The need for clarification regarding the utility of self-monitoring of blood glucose (SMBG) was initially addressed in a position statement published in April 2004 (Owens et al, 2004). This need was heightened because of the suggestion by some UK primary care trusts (PCTs) – on the recommendation of their pharmaceutical advisors – to restrict patients with diabetes to one blood glucose test per day irrespective of diabetes type or therapeutic regimen. Some authorities in the UK have since developed local guidelines for SMBG based on the original position statement (Owens et al, 2004), aimed at clarifying the requirements for blood glucose test strips in the different categories of persons with diabetes (Rhondda Cynon Taff Local Health Board, 2004; Wycombe PCT, 2005). The National Institute for Clinical Excellence (NICE) guidance (NICE, 2002), while emphasising the need for SMBG did not prescribe the necessary frequency of blood glucose testing required by the different patient groups, or how it should relate to specific situations. There is evidence available that the more frequent the SMBG, the better the HbA1c regardless of diabetes type or therapy (Karter et al, 2001).

Since the original multidisciplinary consensus statement was published (Owens et al, 2004), we have further attempted to obtain a wider consultation by involving 292 additional diabetes-related healthcare professionals from across the UK. The subsequent discussions confirmed that most of the initial recommendations/statements were well understood and accepted but that some needed further clarification. In this article, we aim to describe the measures taken to widen the debate based on the original proposals in an attempt to provide as clear statements as possible in support of the appropriate use of SMBG in persons with diabetes (see Appendices 1 and 2).

Consensus position: widening the debate
In order to evaluate the level of agreement amongst the diabetes care multidisciplinary team regarding the original 32 consensus statements, a number of workshops were conducted across the UK. These were held at six different locations (Birmingham, Cardiff, Glasgow, London, Manchester and York) during 2004 in an attempt to accommodate any possible regional differences in opinion and practice. Delegates included diabetes specialist nurses (DSNs), pharmaceutical advisors, general practitioners (GPs), hospital clinicians, practice nurses, primary care trust (PCT)/local health board (LHB) personnel and a small number of patients.

These workshops provided participants with the opportunity to express and record their responses to any of the original statements and also provide alternative proposals. The term ‘consensus’ was initially defined as >50 % agreement for each statement when discussed at the regional meetings. Only two statements failed to achieve this level of agreement, with 17 out of the 32 statements (53 %) achieving >90 % agreement after debate. Where there was a low level of consensus with the original statements alternative wordings were proposed. The feedback from the workshops resulted in the construction of a number of proposed alternative statements, which were returned to the participants in the form of a questionnaire to elicit preferences. The responses were then analysed and discussed by the ‘consensus group’ to arrive at the final statements included in Appendix 2. Key elements in the various discussions are presented below.

Issues for clarification
The relationship between different indices of glycaemic control
Although the two most widely used measures of diabetes control – blood glucose and glycated haemoglobin (HbA1c) concentrations – are well known to healthcare practitioners, there is still considerable confusion about the most appropriate use of these glycaemic indices. Understanding the relationship between these indicators is central to the recommendations relating to their use in the management of a given person with diabetes.

Blood glucose
In diet-treated type 2 diabetes, both the basal and the postprandial blood glucose concentrations are elevated compared to persons without diabetes, and the pattern is generally predictable from day to day (Pickup, 2003). For this reason, a single fasting or random blood glucose test is a fairly good measure of the ‘diabetic control’ and the average blood glucose concentration (Holman and Turner, 1981). Both fasting and single glucose values throughout the day correlate with HbA1c (which is a measure of mean blood glucose level – see below) in type 2 diabetes (Gonen et al, 1979; Avignon et al, 1997; Bonora et al, 2001).

There has been a divergence of views as to whether the fasting/preprandial or the postprandial blood glucose test relates best to overall control and HbA1c in type 2 diabetes. Some authors have found the best correlation with HbA1c for non-fasting (postprandial) glucose (Avignon et al, 1997), while others found the best relationship between HbA1c and fasting blood glucose levels (Bonora et al, 2001). This discrepancy may be explained by a recent study (Monnier et al, 2003), which showed that the relative contribution of fasting blood glucose concentration to overall glycaemia increases as control worsens (HbA1c increasing). Thus, a fasting blood glucose test is likely to be a better measure of overall control in the poorly-controlled type 2 patient (with an HbA1c above about 7.5%) and a postprandial blood glucose test the better index in the better-controlled patient (HbA1c <7.5 %). One should therefore consider determining the postprandial blood glucose wherever the fasting blood glucose is normal or near normal but the HbA1c remains elevated (>7.5 %).

The progression from lifestyle measures alone (diet, weight management and physical exercise) to the additional requirement for insulin secretagogues (sulphonylureas, metaglinides) or insulin therapy in type 2 diabetes is accompanied by an increased risk of hypoglycaemia. This increased risk is more apparent with insulin therapy, which therefore demands greater frequency of blood glucose testing during the transition (Owens et al, 2004).

In type 1 diabetes, however, the blood glucose level often varies widely throughout the day, ranging from hypo- to hyperglycaemia, and the pattern is often unpredictable both within and between days (Pickup, 2003). This has been amply demonstrated by recent continuous in vivo blood monitoring using a glucose sensor (Sachedina and Pickup, 2003). It is for this reason that one or two clinic or home blood glucose tests give only limited information about such variations in persons with type 1 diabetes. Therefore, a timed series of blood glucose measurements during the day is essential to assess the quality of glycaemic control in this type of diabetes. The more erratic the blood glucose oscillations in a given patient, the more frequent the necessary testing. As expected in type 1 diabetes, there is no correlation between a single blood glucose test and HbA1c (McCance et al, 1988).

Glycated haemoglobin and HbA1c
Glycated haemoglobin is a measure of the average blood glucose control over the preceding two-to-three months. This arises because, over the lifetime of the red blood cell (about 120 days), glucose and sugar phosphates slowly attach (glycate) by a covalent but non-enzymatic mechanism to sites (N-terminal and ε-amino groups) on the haemoglobin molecule (Pickup, 2003). HbA1c is the glycated haemoglobin component present in largest amount and the one measured most often in clinical practice; it is formed by the attachment of glucose to the N-terminal of the β-chain of haemoglobin. As the rate of glycation is proportional to the ambient glucose concentration, the percentage of haemoglobin glycated thus reflects average preceding glucose levels. In fact, the HbA1c concentration is weighted towards glycaemia in the month preceding testing (Tahara and Shima, 1995).

Many studies show that glycated haemoglobin correlates strongly with the mean blood glucose concentration over the previous months (e.g. Paisey et al, 1980; Bonora et al, 2001; Rohlfing et al, 2002; Derr et al, 2003), even in type 1 diabetes where the glucose levels show wide oscillations. There is no evidence that HbA1c is influenced by glycaemic oscillations (Derr et al, 2003) and therefore the HbA1c cannot distinguish between a mean level of glycaemia with little variation and one with wide variation around the average blood glucose level. An HbA1c of 5.5 %, for example, may therefore either represent excellent control with a mean blood glucose concentration of 5mmol/l or poor control with the same mean blood glucose concentration of 5 mmol/l but frequent episodes of hypo- and hyperglycaemia.

HbA1c is incapable of assessing hour-by- hour changes in blood glucose level, which is often necessary for optimising insulin dosage for the different insulin preparations. It is for this reason that HbA1c is unsuitable as a solitary measure of glycaemic control in diabetes patients with highly variable and unpredictable glucose levels when hypoglycaemia is a significant risk, e.g. type 1 and type 2 patients on insulin therapy and also type 2 patients taking insulin secretagogues. HbA1c is an important index of long-term control in both type 1 and type 2 patients and can be the sole measure in persons with type 2 diabetes on diet and oral agents that are not normally associated with hypoglycaemia (metformin and glitazones) when used without the concomitant use of insulin secretagogues or insulin.

In view of the well recognised limitations with the use of HbA1c, it is surprising that the UK National Prescribing Centre (2002) has made a general statement that:

‘Measuring HbA1c levels is, therefore, likely to provide more information about glycaemic control than day-to-day monitoring of blood glucose’ (National Prescribing Centre, 2002).

Moreover, we note that many clinical trials and surveys continue to evaluate diabetes control utilising a variety of different indices and frequencies of monitoring. The continued use of HbA1c as the only outcome measure thus ignores the well recognised glycaemic oscillations that occur from day to day, which are a more accurate representation of the individual patient’s glycaemic status (e.g. Faas et al, 1997; Evans et al, 1999; Coster et al, 2000).

Fructosamine
Fructosamine is essentially glycated serum protein, mainly albumin, and is formed in an analogous manner to the glycation of haemoglobin (Austin et al, 1999). Since albumin has a half-life of about 17 days, fructosamine is an index of integrated glycaemic control over a much shorter time than HbA1c, i.e. over the preceding two weeks or so. In clinical practice, fructosamine has been used as an alternative measure of ‘long- term’ control, particularly when there is interference with HbA1c assays in persons with haemoglobinopathies and when glycaemic control is changing rapidly, such as during pregnancy in people with diabetes (Kilpatrick, 1997; Pickup, 2003). As a measure of long-term control in diabetes, it has the same provisos as HbA1c, being insensitive to blood glucose variations.

The measurement of fructosamine is now less often used than HbA1c. HbA1c has a well- established place in the assessment of overall diabetes control (Diabetes Control and Complications Trial [DCCT] Research Group, 1993; United Kingdom Prospective Diabetes Study [UKPDS] Group, 1998) and is regarded as the primary indicator for assessing risk of developing diabetes-related complications due to dysglycaemia.

Urine glucose
Urine glucose testing used to be the routine method of assessing diabetes control before the advent of SMBG. It is an extremely unreliable measure of blood glucose levels (Tattersall and Gale, 1981) and has largely been abandoned.

Glycosuria occurs when the renal threshold for glucose is exceeded, which is usually 10 mmol/l. The threshold varies between individuals and to a lesser extent within the same person from day to day. Therefore, marked hyperglycaemia may well occur without the presence of glycosuria. The presence of a high threshold, or marked glycosuria may be evident during periods of normal blood glucose due to a reduced renal threshold for glucose, e.g. during pregnancy. The urine glucose can also be affected by fluid intake by concentrating or diluting the urine. The urine glucose result does not reflect the blood glucose concentration at the time of testing and only approximates over the time that the urine has been produced (American Diabetes Association [ADA], 2003).

Therefore, urine glucose concentration is a very crude indicator of glycaemic control in persons with diabetes. It has largely been abandoned and replaced by HbA1c measurements, supplemented by SMBG as deemed necessary in the circumstance (Owens et al, 2004).

The new General Medical Services (nGMS) Contract and SMBG: A surprising deficiency
The new GP contract was introduced in the UK in April 2004 (British Medical Association, 2004). It has a Quality and Outcomes Framework, which rewards GPs for achieving levels of process and outcome in various domains. There are 99 points that can be achieved through the fulfilment of 18 indicators in the clinical sphere of diabetes. None specifically mentions blood glucose monitoring. However, 27 of the points relate to HbA1c levels, of which 16 points will be awarded for achieving an HbA1c of 7.4% or less in 50 % of the people with diabetes on the practice register, and 11 points for obtaining a HbA1c of 10% or less in 85%.

SMBG is an essential procedure in any attempt to achieve these important treatment goals (HbA1c targets). It can enable those with poor overall glycaemic control to monitor their day-to-day blood glucose levels, and understand the relationship between their prescribed treatment, food intake and physical activity. It also enables concordance between these various factors to achieve near normoglycaemia while avoiding hypoglycaemia. For people with diabetes who require insulin treatment, blood glucose monitoring is mandatory to enable appropriate insulin dose adjustments to be made to optimise glycaemic control and achieve the HbA1c targets stated in the Quality and Outcomes Framework.

Differences in patterns of glycaemic control in type 1 and type 2 diabetes
As has been discussed, in patients with type 2 diabetes, blood glucose levels tend to be more predictable on a day-to-day basis, with no wide swings in blood glucose concentration, as are so commonly seen in patients with type 1 diabetes (Pickup, 2003).

There are other well-recognised differences between these two major types of diabetes which are relevant to these discussions. The UKPDS showed clearly that type 2 diabetes is a progressive disease, with gradual and almost inevitable deterioration in glycaemic control over time (UKPDS Group, 1998) requiring adjustments to be made in therapy and accompanying monitoring. In contrast, patients with type 1 diabetes have essentially similar monitoring requirements to achieve satisfactory levels of diabetes control, based on HbA1c and SMBG over many years, even decades.

In patients with type 2 diabetes, disease progression has not been shown to be influenced by commonly used hypoglycaemic agents, i.e. metformin, sulphonylureas or even insulin (UKPDS Group, 1998). Preliminary studies with insulin sensitisers (e.g. glitazones) suggest that preservation of glycaemic control in subjects with type 2 diabetes may be more feasible. The future involvement of other agents such as GLP-1 analogues or DPPIV inhibitors may be important, although much more work needs to be done in this area (Campbell, 2004; Serdy and Abrahamson, 2004; Habener, 2001). For the above reasons, particularly in the context of primary care, management of glycaemic control should be considered differently for persons with type 1 and the majority of people with type 2 diabetes.

Opportunistic testing two weeks prior to a clinic visit
When the person with diabetes is unable or unwilling to perform regular SMBG, consideration should be given to requesting the patient to carry out monitoring during the two weeks prior to a clinic visit. In the absence of more comprehensive data, this option, although limited, could form some basis for discussion with the patient during the clinic appointment.

Frequency of testing in pregnancy
In type 1 diabetes, poor glycaemic control at the time of conception and during pregnancy adversely influences the outcome (Temple et al, 2002; Evers et al, 2004, Jensen et al, 2004). Daily SMBG is associated with lower HbA1c values and a lower incidence of adverse outcomes such as congenital malformation (de Veciana et al, 1995; Jensen et al, 2004). The optimal frequency and timing of blood glucose testing in pregnancy has yet to be established (Homko and Reece, 2002). Current recommendations on the frequency of SMBG during pregnancy are therefore based largely on expert opinion rather than trial evidence (Homko and Reece, 2002). The recommended frequency of testing is similar in gestational diabetes treated with diet, as for those on insulin.

Diabetes UK advises that pregnant women should measure their blood glucose frequently (Diabetes UK, 2004). More specifically, however, guidance from the Scottish Intercollegiate Guidelines Network (SIGN) recommends maintaining blood glucose within the range of 4–7 mmol/l, and suggests that this will require carrying out SMBG 4–6 times daily (SIGN, 2001). The ADA does not stipulate the frequency of SMBG, but suggests aiming for preprandial values of 3.9–5.6mmol/l and two-hour postprandial values of <7.8 mmol/l during the pre- conceptual period (ADA, 2002). The risk of hypoglycaemia is greatest in the first trimester (Evers et al, 2002), so more frequent testing may be necessary at this and other times during pregnancy to improve glycaemic control whilst avoiding hypoglycaemia.

SMBG in patients with type 2 diabetes on diet and exercise It is widely recognised that HbA1c measurements in type 2 diabetes treated by diet and exercise alone, and by metformin and glitazones, are a good guide to the status of diabetes control, and the recommended frequency of this test is 3–6 monthly (UKPDS Group, 1998). This, however, may not always be carried out routinely in primary care, and in other circumstances where HbA1c testing is not available, SMBG is the preferred substitute for monitoring glycaemic control. Patients may be exposed to increasing blood glucose levels without much change in HbA1c during the early phase of type 2 diabetes. Bonora et al (2001) found that many type 2 patients had a postprandial blood glucose >8.9 mmol/l even when HbA1c was below 7%. It is therefore important to recognise not only the relentless progression of type 2 diabetes but also perhaps the subtle changes in glycaemic control that can be detected by SMBG.

Educating patients on the principles of SMBG should not be in isolation but as an integral part of the patient’s self-care plan, taking into consideration the individual’s knowledge, abilities, needs and fully informed choice (Department of Health, 2002).

Diabetes education includes motivating the patient to carry out lifestyle changes such as increased activity, improved diet and weight management to avoid obesity. There is plenty of evidence to suggest that newly diagnosed type 2 patients can achieve substantial improvement in their HbA1c levels initially, but unfortunately this is not sustained in the medium- to long-term due to the lack of adherence and motivation (UKPDS, 1998). SMBG may have a role in educating the patient about the impact of certain foods and exercise patterns. Knowing the pre- and post- exercise blood glucose level allows an individual to recognise the benefits of increased activity, and to achieve these safely. For the obese person with diabetes, a reduction in weight will result in lower blood glucose, which in the self-monitored patient may increase motivation and encourage the individual to continue to improve. In the patient who is empowered but indulges in occasional dietary indiscretions, SMBG may alert them to the adverse consequences on blood glucose levels and the need to ‘come back on track’.

Evidence in this area is currently sparse, but there is support for the notion that meal-related SMBG can improve at least some patients with type 2 diabetes (Schwedes et al, 2002).

SMBG in children and adolescents with diabetes
NICE guidelines state that children and young people with diabetes should be encouraged to perform frequent blood glucose monitoring because this is associated with improved HbA1c levels (NICE, 2004). Unfortunately, optimal glycaemic control is rarely achieved in children and young people with diabetes (Mortensen and Hougaard, 1997). Variable eating habits and exercise patterns (particularly in younger children), insulin resistance during puberty (Raine et al, 2001) and psychosocial problems during adolescence can contribute to erratic blood glucose control.

In childhood diabetes, poor glycaemic control has many consequences over and above those applicable to the adult population. In addition to the increased risk of complications in later life, poor diabetes control can adversely affect children’s growth and development. Although the relationship between abnormal growth and development and metabolic control is difficult to define (Dunger, 1994), inadequate insulin therapy can cause delayed puberty and impaired growth (Raine et al, 2001).

Therefore, children and young people with diabetes should adjust their insulin dosage requirements according to their blood glucose measurements (NICE, 2004). The recommendations for blood glucose monitoring for adult people with type 1 diabetes equally apply to the paediatric population.

Regional meetings to debate the ‘Consensus Guidelines’
During 2004, a series of six workshops were held across the UK, attended by diabetes care professionals to debate the original ‘Consensus Guidelines’ (Owens et al, 2004). A total of 307 delegates from several diabetes-related disciplines attended the meetings (see below). Feedback from the regional meetings revealed that 96 % of delegates felt they had benefited from the discussions during the workshops and that 88% planned to make changes to their working practice as a direct result.

The workshop programme also allowed discussion of both local and national issues relating to diabetes care, providing input to the debate for the purpose of achieving a consensus on SMBG. At each workshop, two identical questionnaires relating to SMBG were issued to all attendees, one at the beginning of the session and one after the debate. The questionnaires were designed to assess the level of agreement with the 32 original ‘consensus’ statements (Owens et al, 2004). Out of 307 participants, the final sample consisted of 292 participants who submitted completed questionnaires.

Table 1 demonstrates that there were a similar number of participants at each meeting. Distribution of attendees by role and healthcare sector is shown in Tables 2 and 3. The majority of workshop attendees were DSNs, who are the most actively involved professional group in the day-to-day practice of SMBG (Table 2).

Following discussion at the workshops, it was observed that for half of the original ‘consensus’ statements there was agreement of greater than 90 % (+/- 3.4 %, 95 % CI) and for over three quarters, agreement of greater than 70 % (+/- 5.2 %, 95 % CI) was observed.

The debate concerning SMBG resulted in a higher level of agreement (Table 4). Further evaluation of the dataset revealed significant differences in levels of agreement between DSNs and PCT staff who attended the debating sessions.

The difference of opinion, demonstrated across the different professional groups supports the need for continuing dialogue between the clinical and managerial arms of each PCT/LHB. As a basis for such discussion, a policy statement would serve to ensure that there is equity of care with respect to SMBG nation-wide.

The questionnaires provided the participants with the facility to record their objections to any of the original statements and provide alternative wordings. Following a thorough review of the comments, it was found that most of the disagreements were semantic, rather than conceptual, although a number of suggested changes and amendments were proposed. A structured approach was adopted to finalise the five statements which were in the bottom quartile with regard to level of agreement, and for which the respondents registered the greatest number of objections (Table 5).

A third questionnaire was mailed to the 292 participants, who were asked to rank their preference for proposed new wordings for each of the five statements by scoring each new wording from 1–5 according to preference. One-hundred-and-thirty-eight (47.3 %) completed questionnaires were received. The responses were analysed by summating the ranking for each statement, so that if a respondent gave two or more options the same ranking, analysis would reflect the equal standing of these options. The frequency distribution for each option with respect to the different ranks was used to assess the level of consensus and indicate the most preferred wording for each of the statements.

This ‘consensus’ group reviewed all of the suggested alternatives and amended where felt necessary the wording of the original statements (Table 6).

The revised consensus guidelines are contained in Appendix 2, where they are presented and expanded into a table to include the full 32 position statements. These are intended as recommendations to healthcare professionals on SMBG in persons with diabetes.

American Diabetes Association (2003). Test of glycemia in diabetes. Diabetes Care 26: S106–8
American Diabetes Association (2002) Position Statement: Preconception care of women with diabetes. Diabetes Care 25 (Suppl 1): S82–S84
Austin GE, Wheaton R, Nanes MS, Rubin J, Mullins RE (1999) Usefulness of fructosamine for monitoring outpatients with diabetes. American Journal of Medical Sciences 318: 316–23
Avignon A, Radauceanu A, Monnier L (1997). Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 20: 1822–26
British Medical Association (2004) Investing in general practice: the new general medical services contract. Available at http://www.bma.org.uk/ap.nsf/Content/ investinggp (accessed 17.03.05)
Bonora E, Calcaterra F, Lombardi S, Banfante N, Formentini G, Bonadona RC, Muggeo M (2001). Plasma glucose levels throughout the day and HbA1c interrelationships in type 2 diabetes. Diabetes Care 24: 2023–29
Campbell IW. (2004) Long-term glycaemic control with pioglitazone in patients with type 2 diabetes. International Journal of Clinical Practice 58(2): 192–200
Coster S, Gulliford MC, Seed PT, Powrie JK, Swaminathan R (2000). Self-monitoring in type 2 diabetes mellitus: a meta-analysis. Diabetic Medicine 17: 755–61
de Veciana M. Major CA. Morgan MA. Asrat T. Toohey JS. Lien JM. Evans AT (1995) Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. New England Journal of Medicine 333(19): 1237–41
Derr R, Garrett E, Stacy GA, Saudek CD (2003). Is HbA1c affected by glycemic instability? Diabetes Care 26: 2728–33
Department of Health (2002) National Service Framework for Diabetes. DoH, London. Available at: http://www.publications.doh.gov.uk/nsf/diabetes/ (accessed 17.03.05)
Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes. New England Journal of Medicine 329: 977–86
Diabetes UK (2004) Care Recommendation: Recommendation for the management of pregnant women with diabetes (including gestational diabetes). Diabetes UK, London. Available at www.diabetes.org.uk/ infocentre/carerec/preg4.doc. (accessed on 17.03.05)
Dunger DB (1994) Endocrine evolution, growth and puberty in relation to diabetes. In Kelnar C J H (ed) Childhood and Adolescent Diabetes. Chapman & Hall Medical, London: 75–87
Evans JMM, Newton RW, Ruta DA, MacDonald TM, Stevenson RJ, Morris AD (1999). Frequency of blood glucose monitoring in relation to glycaemic control: observational study with diabetes database. British Medical Journal 319: 83–68
Evers IM, de Valk HW, Visser GH. (2004) Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands. British Medical Journal 328: 915–19
Evers IM, ter Braak EW, de Valk HW, van der Schoot B, Janssen N, Visser GH. (2002) Risk indicators predictive for severe hypoglycemia during the first trimester of type 1 diabetic pregnancy. Diabetes Care 25: 554–59
Faas A, Schellevis FG, van Eijk JT (1997). The efficacy of self-monitoring of blood glucose in NIDDM subjects: A criteria-based literature review. Diabetes Care 20: 1482–86.
Gonen B, Rochman H, Rubenstein AH (1979). Metabolic control in diabetic patients: assessment by hemoglobin A1 values. Metabolism 28(4 Suppl 1): 448–52
Habener J (2001) Glucagonlike peptide-1 agonist stimulation of ß-cell growth and differentiation. Current Opinion in Endocrinology and Diabetes 8: 74–81
Holman RR, Turner RC (1981). The basal plasma glucose: a simple index of maturity-onset diabetes. Clinical Endocrinology 14: 275–86
Homko CJ, Reece EA. (2002) Self-monitoring of blood glucose in gestational diabetes. Journal of Maternal and Neonatal Medicine 12: 389–95
Jensen DM, Damm P, Moelsted-Pedersen L, Ovesen P, Westergaard JG, Moeller M, Beck-Nielsen H (2004) Outcomes in type 1 diabetic pregnancies: A nationwide, population-based study. Diabetes Care 27: 2819–23
Karter AJ, Ackerson LM, Darbinian JA, D’Agostino RB Jr, Ferrara A, Liu J, Selby JV (2001) Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes registry. American Journal of Medicine 111: 1–9
Kilpatrick ES (1997). Problems in the assessment of glycaemic control in diabetes mellitus. Diabetic Medicine 14: 819–31
McCance DR, Ritchie CM, Kennedy L (1988). Is HbA1 measurement superfluous in NIDDM? Diabetes Care 11: 512–14
Monnier L, Lapinski H, Colette C (2003) Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients. Diabetes Care 26: 881–85
Mortensen HB, Hougaard P (1997). Comparison of metabolic control in a cross-sectional study of 2,873 children and adolescents with IDDM from 18 countries. The Hvidore Study Group on Childhood Diabetes. Diabetes Care 20(5): 714–20
National Institute for Clinical Excellence (NICE) (2004) Type 1 diabetes: diagnosis and management of type 1 diabetes in children and young people. NICE, London. Available at www.nice.org.uk/page.aspx?o=213902 (accessed 17.03.05)
NICE (2002) Management of type 2 diabetes – Managing blood glucose levels (Guideline G). NICE, London. Available at http://www.nice.org.uk/page.aspx?o=36738 (accessed 17.03.05)
National Prescribing Centre (2002) When and how should patients with diabetes mellitus test blood glucose? MeReC Bulletin 13(1). Available at http://www.npc.co.uk/MeReC_Bulletins/2002Volumes/ vol13no1.pdf (accessed 17.03.05)
Owens D, Barnett AH, Pickup J, Kerr D, Bushby P, Hicks D et al (2004). Blood glucose self-monitoring in type 1 and type 2 diabetes: reaching a multidisciplinary consensus. Diabetes and Primary Care 6: 8–16
Paisey RB, Macfarlane DG, Sherriff RJ, Hartog M, Slade RR, White DA (1980) The relationship between blood glycosylated haemoglobin and home capillary blood glucose levels in diabetics. Diabetologia 19(1): 31–4
Pickup JC (2003). Diabetic control and its measurement. In: Pickup JC and Williams G (Eds), Textbook of Diabetes, 3rd Edition. Blackwell Publishing, Oxford: 34.1–34.17
Raine JE, Donaldson MDC, Gregory JW, Savage MO (2001) Practical endocrinology and diabetes in children. Blackwell Science, Oxford
Rhondda Cynon Taff Local Health Board (2004) Diabetes Desktop Guidelines. Rhondda Cynon Taff Local Health Board, Treforest
Rohlfing CL, Wiedmeyer H-M, Little RR, England JD, Tennill A, Goldstein DE (2002). Defining the relationship between plasma glucose and HbA1c in the Diabetes Control and Complications Trial. Diabetes Care 25: 275–78
Sachedina N, Pickup JC (2003) Performance assessment of the Medtronic-MiniMed Continuous Glucose Monitoring System and its use for measurement of glycaemic control in type 1 diabetic subjects. Diabetic Medicine 20: 1012–15
Scottish Intercollegiate Guidelines Network (SIGN) (2001) Section 8: Management of diabetes in pregnancy In: SIGN Publication No 55: Management of diabetes. SIGN, Edinburgh: 34–38
Schwedes U, Siebolds M, Mertes G (2002) Meal-related structured self-monitoring of blood glucose: effect on diabetes control in non-insulin-treated type 2 diabetic patients. Diabetes Care 25: 1928–32
Serdy S, Abrahamson MJ (2004) Durability of glycemic control: a feature of the thiazolidinediones. Diabetes Technology & Therapeutics 6(2): 179–89.
Tahara Y, Shima K (1995). Kinetics of HbA1c, glycated albumin and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care 18: 440–47
Tattersall RB, Gale E (1981). Patient self monitoring of blood glucose and refinements of conventional insulin treatment. American Journal of Medicine 70: 177–82
Temple R, Aldridge V, Greenwood, R, Heyburn P, Sampson M, Stanley, K. (2002) Association between outcome of pregnancy and glycaemic control in early pregnancy in type 1 diabetes: population based study. British Medical Journal 325: 1275-76
UK Prospective Diabetes Study Group (1998). Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837–53
Wycombe PCT Diabetes Testing Steering Group (2005) Now You Are Monitoring Blood Glucose – What Next? Wycombe PCT, High Wycombe

Share this article
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp
Related content
For the latest news and articles

Sign up to all DiabetesontheNet journals

© Copyright Omniamed Communications. All Rights Reserved​
108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom​
Omniamed logo white
DiabetesontheNet Logo
For the latest news and articles

Sign up to all DiabetesontheNet journals

 

By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

DiabetesontheNet Logo

This website is for UK healthcare professionals only. To continue, please confirm that you are a UK healthcare professional below.